Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process

Core Insights - Trinity Biotech is undergoing a comprehensive transformation plan with a focus on developing its continuous glucose monitoring (CGM) technology, appointing Barclays Capital as its exclusive financial advisor to support this strategic realignment [1][3][4] - The company's board and management have identified CGM technology and related data-driven insights as the primary strategic focus moving forward, highlighting the significant market potential of this technology [2][4] - Successful execution of the transformation plan is expected to enhance near-term profitability and create opportunities for portfolio optimization and CGM-related growth [3][4] Company Overview - Trinity Biotech is a commercial-stage biotechnology company specializing in human diagnostics and diabetes management solutions, including wearable biosensors [6] - The company develops, acquires, manufactures, and markets diagnostic systems for point-of-care and clinical laboratory segments, recently entering the wearable biosensor market through the acquisition of Waveform Technologies Inc. [6][7] - Trinity Biotech's products are utilized for detecting infectious diseases and quantifying various chemistry parameters in blood samples, with a distribution network spanning over 75 countries [7]